Nauzer Forbes

Oct 5, 2024 | onlinelibrary.wiley.com | Nauzer Forbes |Jackie Bosch |John Eikelboom

Dear Editors, We thank Dr. Yang et al. for their interest in our study [1]. In their letter [2], they suggested that our analysis of the incidence and predictors of major gastrointestinal bleeding in patients on aspirin 100 mg once daily, rivaroxaban 5 mg twice daily or the combination of aspirin 100 mg once daily and rivaroxaban 2.5 mg twice daily had ‘critical’ limitations [1]. First, they suggested that we ‘neglected’ to report long-term outcomes after major acute bleeding.